Symbols

DCOY

Decoy·NASDAQ

--(--)

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About DCOY

Decoy Therapeutics Inc.

Industry

Pharmaceutical

Established Date

02/26/2014

Listing Date

01/29/2015

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.salariuspharma.com

Security Type

Common stock

Office address

2450 Holcombe Blvd., Suite J-608, Houston, Texas 77021

Business

Introduction

Decoy Therapeutics Inc., a biotechnology company incorporated in Delaware on February 26, 2014, and its operations are primarily located in Boston, Massachusetts. The company is a clinical-stage biopharmaceutical company focused on developing innovative treatment options for cancer patients. Its product portfolio includes seclidemstat, a lead drug candidate currently in a Phase 1/2 clinical study at MD Anderson Cancer Center, designed to target hematological cancers such as myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML), especially for patients with limited treatment options. In addition, the company is also advancing SP-3164, an oral small molecule protein degrading agent, which is currently in the new drug research phase (IND).

Company Financials

EPS

DCOY has released its 2025 Q2 earnings. EPS was reported at -0.45, versus the expected -1.02, beating expectations. The chart below visualizes how DCOY has performed over recent quarters, highlighting trends in earnings surprises.